NDMA is classified as a probable human carcinogen. Exposure to this compound can increase cancer risk as well as organ and bone marrow damage, tumors, and gene mutation.
The U.S. Food and Drug Administration (FDA) has found N-Nitrosodimethylamine (NDMA) levels in excess of the Acceptable Daily Intake Limit (ADI) in tested lots of 500mg and 750mg Extended-Release Metformin tablets. Current FDA testing has not shown NDMA impurity in Immediate Release (IR) Metformin products (the most commonly prescribed type of metformin).
There are additional manufacturers of the Metformin ER formulation that supply a significant portion of the U.S. market, and their products are not being recalled. The FDA is continuing to work closely with manufacturers to ensure appropriate testing. Assessments are underway to determine whether Metformin ER recalls will result in shortages and the agency will work closely with manufacturers to prevent mor reduce any impact of shortages.
More on Recent NDMA Contamination & Recalls
Recently the FDA ordered the popular heartburn drug Zantac, and other ranitidine generics, be pulled from the market immediately, citing an unacceptable level of NDMA impurity.
NDMA contamination has been triggering warnings and recalls on multiple drugs. At Terrell Hogan we strive to keep you informed. Reviewing medication recalls and regularly consulting with a healthcare professional is a good idea when taking prescription drugs.